Genetic clues may predict when Friedreich's ataxia begins
NCT ID NCT04346238
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 120 people with Friedreich's ataxia, a rare genetic disease that causes progressive movement problems. Researchers examined tiny interruptions in the DNA expansion that causes the disease to see if they influence when symptoms start and how severe they become. The goal is to better understand the disease, not to test a treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
120 people
The number who actually took part.
- Started
-
Mar 2020
- Finished
-
Dec 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with Friedriech Ataxia genetically confirmed. .
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion criteria: * Subjects with diagnosis of genetically confirmed Friedreich's Ataxia (AF) and : * two expansions of GAAN triplets (\> 100 repetitions or "premutation", corresponding to\> 32 but \<100 repetitions) located in intron 1 of the FXN gene present on the two alleles; * symptomatic (SARA scale\> 4); * having signed a consent for the performance of genetic analyzes which also includes the authorization for the conduct of further studies for research purposes and the authorization for the collection, entry and computer processing of medical data, in all confidentiality. A newsletter on the principle of non-opposition will be sent. Exclusion criteria: * Patients with Friedreich's ataxia due to an expansion associated with a point mutation or a deletion in trans; * Patients who, at the time of signing the genetic consent, objected to the use of their data for research purposes.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Friedreich ataxia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Uh Montpellier
Montpellier, Montpellier, 34295, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a 25-Year global study unlock the secrets of friedreich ataxia?
- Can a missing protein be replaced to slow Friedreich's ataxia?
- Can voice and hearing tests reveal hidden clues to Friedreich's ataxia progression?
- Can advanced heart scans predict the biggest killer in Friedreich's ataxia?
- Video games and AI join the fight against a rare movement disorder
- Can a single gene fix a fatal heart condition? a trial aims to find out